Sofia De Felice

Sofia De Felice

Auto-generated profile, based on publicly available information

Sofia De Felice

Department of Biology, University of Padua, Via Ugo Bassi 58/B, 35131 Padova, Italy

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2025 in iScience
Verified
Journal Article
Open access
FVFilippo Vascon
Filippo Vascon
SFSofia De Felice
Sofia De Felice
MGMatteo Gasparotto
Matteo Gasparotto
SHStefan T. Huber
Stefan T. Huber
CCClaudio Catalano
Claudio Catalano
LCLaura Cendron
Laura Cendron
Antimicrobial resistance poses a severe threat to human health and Pseudomonas aeruginosa stands out among the pathogens responsible for this emergency. The SOS response to DNA damage is crucial in bacterial evolution, influencing resistance development and adaptability in challenging environments, especially under antibiotic exposure. Recombinase A (RecA) and the transcriptional repressor LexA are the key players that orchestrate this process, determining either the silencing or the active transcription of the genes under their control. By integrating state-of-the-art structural approaches with in vitro binding and functional assays, we elucidated the molecular events activating the SOS response in P. aeruginosa, focusing on the RecA-LexA interaction. Our findings identify the conserved determinants and strength of the interactions that allow RecA to trigger LexA autocleavage and inactivation. These results provide the groundwork for designing novel antimicrobial strategies and exploring the potential translation of Escherichia coli-derived approaches, to address the implications of P. aeruginosa infections.

28 October 2026 in Protein Science
Verified
Journal Article
Closed access
PDF file
SFSofia De Felice
Sofia De Felice
CBChristian Buratto
Christian Buratto
ASAlessia Savio
Alessia Savio
MMMaria Morbidelli
Maria Morbidelli
EPEmanuele Papini
Emanuele Papini
LCLaura Cendron
Laura Cendron

11 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SFSofia De Felice
Sofia De Felice
CBChristian Buratto
Christian Buratto
ASAlessia Savio
Alessia Savio
MMMaria Morbidelli
Maria Morbidelli
Emanuele PapiniEmanuele Papini
Emanuele Papini
LCLaura Cendron
Laura Cendron
Human serum albumin (hSA) is the most abundant protein in human plasma, and its pharmacological properties, such as long plasma half-life mediated by the neonatal Fc receptor (FcRn) and its ability to bind endogenous and exogenous molecules, make it attractive for biotechnological applications. Currently, most wild type (WT) SAs are derived from human or bovine serum or produced in yeast and mammalian cells. Although well established, these methods are costly, difficult to reproduce, and not environmentally sustainable. Building on a previous study to design highly mutated hSA sequences, we extend the validation through an in-depth analysis of three engineered hSA variants; hSA1, hSA2, and hSA3, containing 16, 25, or 73 amino acid substitutions, respectively. These variants were designed for enhanced solubility, stability, and expression in Escherichia coli. All three variants showed low- micromolar affinities for hFcRn at pH 5.5, and negligible binding at pH 7.4. In a human endothelial cell-based recycling assay (HERA), the engineered hSA variants were recycled by hFcRn to the same extent as hSA isolated from serum. Exploring the properties of canonical drug-binding sites, warfarin affinity was comparable to WT hSA, whereas ibuprofen binding differed. Complementary cytotoxicity assays on human macrophages confirmed negligible toxicity and biocompatibility. A cryo-electron microscopy structure of hSA3 revealed that, despite extensive engineering, the native heart-shape of hSA, folding of domains, and its open conformation were preserved. These findings validate the structural integrity and functional adaptability of engineered hSA variants, underscoring their potential as versatile, animal-free solutions for next-generation therapeutics and biotechnological applications.

23 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
FVFilippo Vascon
Filippo Vascon
SFSofia De Felice
Sofia De Felice
MGMatteo Gasparotto
Matteo Gasparotto
SHStefan T. Huber
Stefan T. Huber
CCClaudio Catalano
Claudio Catalano
LCLaura Cendron
Laura Cendron
Antimicrobial resistance represents a major threat to human health and Pseudomonas aeruginosa stands out among the pathogens responsible for this emergency. The SOS response to DNA damage plays a pivotal role in bacterial evolution, driving the development of resistance mechanisms and influencing the adaptability of bacterial populations to challenging environments, particularly in the context of antibiotic exposure. Recombinase A (RecA) and the transcriptional repressor LexA are the key players that orchestrate this process, determining either the silencing or the active transcription of the genes under their control. By integrating state-of-the-art structural approaches with binding and functional assays in vitro , we elucidated the molecular events governing the SOS response activation in P. aeruginosa , focusing on the RecA-LexA interaction. Our findings identify the conserved determinants and strength of the interactions that let RecA trigger the autocleavage and inactivation of the LexA repressor. These results provide the groundwork for designing novel antimicrobial strategies and for exploring the potential translation of Escherichia coli -derived approaches, to address the health-threatening implications of bacterial infections. Graphical


10 June 2026
Verified
Dataset
Open access
DSDe Felice Sdf
De Felice Sdf
VFVascon Fv
Vascon Fv
CLCendron Lc
Cendron Lc